Free Trial
NASDAQ:ALMS

Alumis (ALMS) Stock Price, News & Analysis

Alumis logo
$8.54 -1.30 (-13.21%)
Closing price 04:00 PM Eastern
Extended Trading
$8.88 +0.34 (+3.92%)
As of 07:14 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Alumis Stock (NASDAQ:ALMS)

Key Stats

Today's Range
$7.66
$9.70
50-Day Range
$3.57
$9.84
52-Week Range
$3.18
$13.53
Volume
595,988 shs
Average Volume
307,069 shs
Market Capitalization
$403.28 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$26.00
Consensus Rating
Buy

Company Overview

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words "allumer"-French for illuminate-and "immunis"-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule. ESK-001 has demonstrated significant therapeutic effect in our Phase 2 program in patients with PsO, which we define as moderate-to-severe plaque psoriasis (PsO), and is currently being evaluated in an additional Phase 2 clinical trial in patients with systemic lupus erythematosus (SLE), for which we expect to report results in 2026. With the favorable results in our Phase 2 clinical trial in PsO, we intend to initiate multiple Phase 3 clinical trials of ESK-001 in the second half of 2024 in this indication. TYK2 genetic mutations are associated with a strong protective effect in multiple sclerosis, motivating us to develop our second product candidate, A-005, as a CNS-penetrant, allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. In April 2024, we initiated our Phase 1 program of A-005 in healthy volunteers and expect to report initial results by the end of 2024. We utilize our proprietary precision data analytics platform, biological insights and team of experienced research and development experts to deepen our understanding of disease pathologies, accelerate research and development and increase the probability of clinical success. Our collective insights informed our selection of TYK2 as the target for our two lead programs. Beyond TYK2, our proprietary precision data analytics platform and drug discovery expertise have led to the identification of additional preclinical programs that exemplify our precision approach. We recognize that patients living with immune-mediated diseases need alternatives to currently available therapies. Despite recent advances and innovations in the treatment of immune-mediated diseases, many patients continue to suffer, cycling through currently approved therapies while looking for a solution that alleviates the debilitating impact of their disease without life-limiting side effects. Addressing the needs of these patients is why we exist. We are pioneering a precision approach that leverages insights derived from powerful data analytics to select the right target, right molecule, right indication, right patient, right endpoint and right combination to dramatically improve patient outcomes. We believe that combining our insights with an integrated approach to drug development will produce the next generation of treatments to address immune dysfunction. We were founded in January 2021 as a Delaware corporation under the name FL2021-001, Inc. We changed our name to Esker Therapeutics, Inc. in March 2021, and subsequently to Alumis Inc. in January 2022. Our principal executive offices are located at 280 East Grand Avenue, South San Francisco, California.

Remove Ads

Alumis Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
47th Percentile Overall Score

ALMS MarketRank™: 

Alumis scored higher than 47% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Alumis has received a consensus rating of Buy. The company's average rating score is 3.22, and is based on 7 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Alumis has only been the subject of 3 research reports in the past 90 days.

  • Read more about Alumis' stock forecast and price target.
  • Short Interest

    There is no current short interest data available for ALMS.
  • Dividend Yield

    Alumis does not currently pay a dividend.

  • Dividend Growth

    Alumis does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for ALMS.
  • News Sentiment

    Alumis has a news sentiment score of 0.70. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 9 news articles for Alumis this week, compared to 4 articles on an average week.
  • Search Interest

    9 people have searched for ALMS on MarketBeat in the last 30 days.
  • MarketBeat Follows

    Only 1 people have added Alumis to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Alumis insiders have bought more of their company's stock than they have sold. Specifically, they have bought $213,031.00 in company stock and sold $0.00 in company stock.

  • Read more about Alumis' insider trading history.
Receive ALMS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alumis and its competitors with MarketBeat's FREE daily newsletter.

ALMS Stock News Headlines

HC Wainwright Forecasts Alumis' Q1 Earnings (NASDAQ:ALMS)
Q2 Earnings Forecast for Alumis Issued By Leerink Partnrs
Here’s How to Claim Your Stake in Elon’s Private Company, xAI
Even though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks like you… To partner with Elon on what he believes will be the biggest AI project of the century… Starting with as little as $500.
Alumis stock soars on Japan dermatology deal
See More Headlines

ALMS Stock Analysis - Frequently Asked Questions

Alumis' stock was trading at $7.86 on January 1st, 2025. Since then, ALMS shares have increased by 8.7% and is now trading at $8.54.
View the best growth stocks for 2025 here
.

Alumis (ALMS) raised $210 million in an initial public offering on Friday, June 28th 2024. The company issued 13,125,000 shares at a price of $16.00 per share.

Shares of ALMS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Alumis investors own include Comstock (LODE), Ashford Hospitality Trust (AHT), Artificial Intelligence Technology Solutions (AITX), Allakos (ALLK), BioXcel Therapeutics (BTAI), Clearside Biomedical (CLSD) and Delcath Systems (DCTH).

Company Calendar

Today
4/03/2025
Next Earnings (Estimated)
6/18/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ALMS
Previous Symbol
NASDAQ:ALMS
Web
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$26.00
High Stock Price Target
$36.00
Low Stock Price Target
$13.00
Potential Upside/Downside
+202.7%
Consensus Rating
Buy
Rating Score (0-4)
3.22
Research Coverage
9 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
N/A
Market Cap
$405.64 million
Optionable
N/A
Beta
N/A
These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

This page (NASDAQ:ALMS) was last updated on 4/3/2025 by MarketBeat.com Staff
From Our Partners